New molecular targets in bone metastases

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Santini, D ^a   Galluzzo, S ^a   Zoccoli, A ^a   Pantano, F ^a   Fratto, M E ^a   Vincenzi, B ^a   Lombardi, L ^b   Gucciardino, C ^a   Silvestris, N ^c   Riva, E ^a   Rizzo, S ^d   Russo, A ^d   Maiello, E ^b   Colucci, G ^c   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bone metastases; Molecular targets

Indexed keywords

ATRASENTAN; BCR ABL PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CATHEPSIN K; CATHEPSIN K INHIBITOR; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN; ENDOTHELIN 1; EXEMESTANE; ISOPROTEIN; L 006235; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; SARACATINIB; SOMATOMEDIN; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; ZIBOTENTAN; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER TREATMENT INDUCED BONE LOSS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; EPITHELIUM; FIBROBLAST; HOMEOSTASIS; HUMAN; HYPERCALCEMIA; MACROPHAGE; METASTASIS; MICROENVIRONMENT; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; SRC HOMOLOGY DOMAIN; TRANSGENIC MOUSE; TREATMENT DURATION; TUMOR CELL; TUMOR VOLUME; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CATHEPSIN K; ENDOTHELINS; HUMANS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RANK LIGAND;

EID: 78649727076     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70013-X     Document Type: Article

References (38)

1. Coleman RE Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176.
2. Kaplan RN, Rafii S, Lyden D Preparing the " soil" the premetastatic niche. Cancer Res 2006, 66(23):11089-11093.
3. Jung Y, Wang J, Schneider A, et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 2006, 38(4):497-508.
4. Logothetis CJ, Lin SH Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5:21-28.
5. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
6. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
7. Liu XH, Kirschenbaum A, Yao S, Levine AC Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology 2005, 146(4):1991-1998.
8. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003, 95(6):458-470.
9. Guise TA Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88(12 Suppl):2892-2898.
10. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 2007, 40:981-990.
11. Kostenuik PJ Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005, 5:618-625.
12. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 2009, 7(3):2-3.
13. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 2009, 7:11-12.
14. Vadhan-Raj S, Henry DH, von Moos R, et al. Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. J Clin Oncol 2010, 28(Suppl):15s. [abstract 9042].
15. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010, 28(Suppl):18s. [abstract LBA4507].
16. Bagnato A, Spinella F Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003, 14(1):44-50.
17. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003, 21(4):679-689.
18. Carducci MA, Saad F, Abrahamsson PA, et al. Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007, 110(9):1959-1966.
19. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009, 55(5):1112-1123.
20. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998, 273(48):32347-32352.
21. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003, 18(2):222-230.
22. Votta BJ, Levy MA, Badger A, et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 1997, 12(9):1396-1406.
23. Le Gall C, Bellahcène A, Bonnelye E, et al. A Cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007, 67(20):9894-9902.
24. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008, 18(3):923-928.
25. Jensen AB, Olmeo N, Wynne C Ramirez G, et al. Effect of cathepsin K inhibition on suppression of bone resorption in women with breast cancer and established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol 2008, 26(May 20 Suppl). Abstr. 1023.
26. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R Src kinase activity is essential for osteoclast function. J Biol Chem 2004, 279:17660-17666.
27. Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J 2004, 23:790-799.
28. Frame MC Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602:114-130.
29. Marzia M, Sims NA, Voit S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000, 151(2):311-320.
30. Rucci N, Susa M, Teti A Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008, 8(3):342-349.
31. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistance progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27(15S):249s (abstr 5061).
32. Lara PN, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009, 20(3):179-184.
33. Wildes TM, Procknow E, Weilbaecher K, Vij R Effect of dasatinib on bone metabolism in multiple myeloma. J Clin Oncol 2008, 26(May 20 Suppl). Abstr. 8568.
34. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005, 132(1):49-60.
35. Kawano Y, Kypta R Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003, 116:2627-2634.
36. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119:1283-1296.
37. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109(5):2106-2111.
38. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114(2):371-379.